Pediatric Oncology

Selpercatinib is the first targeted cancer therapy for pediatric patients 2 years of age and older with RET gene alterations.

Funded by Childhood Cancer Ireland, Clifton Thornton, PhD, and colleagues will help develop educational support programs for cancer survivors.

The Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy is a first-of-its-kind hub for pediatric Cancer Immunotherapy.

World-class experts will gather at CHOP summit to present on scientific advances in pediatric cancer care in the diagnostics and therapeutic space.

Congratulations to Garrett Brodeur, MD, recipient of the American Society of Pediatric Hematology/Oncology Distinguished Career Award.

This week’s roundup features research exploring the value of well care as voiced by Black adolescent males and their parents. This and more In The News.

This week “In The News,” our scientists and their groundbreaking research appear in Newsweek, Cell Reports, and Molecular Therapy.

In a Q&A, Division of Oncology Chief Stephen P. Hunger, MD, shares what inspires him to conduct research on leukemia.

Pediatric oncology researchers have narrowed down a culprit in an aggressive form of the childhood cancer neuroblastoma that makes the disease progress once tumors form.

Teens with cancer often experience fatigue, pain, and other symptoms that can interfere with these personal goals, which psychologists refer to as health-related hindrance (HRH).